Wyeth Rapamune May Need New U.S. Trial For Cyclosporine-Free Regimen
Executive Summary
Wyeth's proposed Rapamune cyclosporine-free regimen may need another U.S. study before approval, FDA's Antiviral Drugs Immunosuppressive Subcommittee Advisory Committee indicated at its Jan. 24 meeting
You may also be interested in...
Rapamune Labeling Will Reflect “Excess Rate Of Death” In Liver Transplants
Labeling for Wyeth's immunosuppressant drug Rapamune will be updated to reflect "an excess rate of death and graft loss" when used after liver transplant
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011